CC
MACK

Columbia Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Columbia Capital’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1.33M Buy
+14,960
New +$1.09M 1.45% 9

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LIM
Lagoda Investment Management New York $182M AUM 58.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Columbia Capital's MACK Position: Q4 2014 in Review

Columbia Capital opened a new position in Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2014: 14,960 shares worth $1.33M. The stake represents 1.45% of the portfolio and ranks #9 among its holdings.

143 funds tracked by Wall St. Rank hold MACK as of Q4 2014.

  • Columbia Capital held 14,960 shares of Merrimack Pharmaceuticals, Inc. worth $1.33M as of Q4 2014.
  • Merrimack Pharmaceuticals, Inc. was a new Columbia Capital position in Q4 2014.
  • Merrimack Pharmaceuticals, Inc. made up 1.45% of Columbia Capital's portfolio in Q4 2014, its #9 holding.
  • 143 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2014.

Based on Columbia Capital's 13F filing for Q4 2014, filed 11 Feb 2015.